M&A Deal Summary

Purdue Pharma Acquires SpineThera

On October 22, 2018, Purdue Pharma acquired life science company SpineThera

Acquisition Highlights
  • This is Purdue Pharma’s 2nd transaction in the Life Science sector.
  • This is Purdue Pharma’s 2nd transaction in the United States.
  • This is Purdue Pharma’s 1st transaction in Minnesota.

M&A Deal Summary
Date 2018-10-22
Target SpineThera
Sector Life Science
Buyer(s) Purdue Pharma
Deal Type Add-on Acquisition
Advisor(s) Lake Street Capital Markets (Financial)
Fox Rothschild (Legal)

Target

SpineThera

Plymouth, Minnesota, United States
SpineThera, Inc. designs and develops sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SX600, our lead product candidate, is an investigational drug. The company was incorporated in 2012 and is based in Plymouth, Minnesota.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Purdue Pharma

Stamford, Connecticut, United States
Category Company
Founded 1982
Sector Life Science
DESCRIPTION

Purdue Pharma LP is a privately-held pharmaceutical companies known for pioneering research in chronic pain.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (Minnesota) 1 of 1
Country (United States) 2 of 2
Year (2018) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-08 VM Pharma - TrkA Program

United States

VM Pharma - TrkA Program is a provider of important signaling proteins known as tyrosine receptor kinases.

Buy -
Mergr

Product

Company

Legal